BGLC — BioNexus Gene Lab Corp
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1737523 ·
Malaysia
Last close
$1.30
Market Cap
$3.81M
52W High
$5.89
52W Low
$1.07
ADV30
7,715
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 76,156 | 12,982 | -312,018 | -286,451 | 8,726,423 | 1,232,658 | 947,981 |
| Mar 2026 | 22,842 | -790 | -571,433 | -543,575 | 9,040,130 | 3,964,962 | 946,877 |
| Dec 2025 | 483,760 | -3,983 | -1,032,000 | -1,036,117 | 9,252,784 | 4,039,705 | 637,856 |
| Sep 2025 | 2,543,823 | 377,685 | -810,269 | -708,991 | 7,621,228 | 1,153,121 | 804,966 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,161,981
Investing CF
$946,409
Financing CF
$359,410
CapEx
$-28,244
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.31
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,970,802
Inventory
$667,154
Receivables
$230,454
ST Investments
$1,741,532
EBIT TTM
$-2,887,137
Pretax Income TTM
$-2,904,855
Interest Exp TTM
$17,718
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,126,581
EBITDA
$-2,640,000
Free Cash Flow
$68,315
Enterprise Value
$1,524,506
Total Cash
$3,521,532
Total Debt
$323,197
Shares Out
2,933,442
Trailing EPS
$-1.26
Book Value
$3.22
ROE
-33.7%
ROA
-19.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,424,911 | -3,158,450 | -2,984,607 | 9,252,784 | 637,856 | 8,614,928 | -1,838,382 |
| Dec 2024 | 9,510,646 | -1,956,763 | -1,598,342 | 10,433,848 | 2,111,044 | 8,322,804 | -2,093,260 |
| Dec 2023 | 9,770,806 | -3,079,624 | -2,629,043 | 11,399,793 | 1,741,941 | 9,657,852 | -1,822,212 |
| Dec 2022 | 10,928,707 | -291,177 | -355,966 | 8,740,162 | 2,075,149 | 6,665,013 | 551,822 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRTX | BioRestorative Therapies, Inc. | $3.19M | $2.31 | — |
| BMGL | Basel Medical Group Ltd | $5.43M | $3.47 | — |
| HLYK | HealthLynked Corp | $5.81M | $1.97 | — |
| BICX | BioCorRx Inc. | $5.98M | $0.20 | — |
| CDIX | Cardiff Lexington Corp | $6.57M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
2026-07-28 13:00 · Yahoo
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
2026-05-29 13:00 · Yahoo
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
2026-03-11 12:45 · Yahoo
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
2026-02-23 13:30 · Yahoo
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
2026-01-28 14:00 · Yahoo
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
2025-12-01 13:00 · Yahoo
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
2025-11-12 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.